Unapproved Weight-Loss Drug Reta Being Sold Illegally on Belfast Social Media as Hospitals Report Serious Side Effects
Health authorities in Northern Ireland have issued urgent warnings about the widespread illegal sale of retatrutide — marketed on social media as 'Reta' — an unapproved weight-loss drug that is being traded on Facebook and other platforms in Belfast and across Northern Ireland, with medical experts reporting a rise in patients presenting at hospitals with serious side effects including kidney disease and severe vomiting after obtaining the drug from unregulated sources including personal trainers at gyms.
Background
Retatrutide is an investigational molecule currently being developed by the pharmaceutical company Eli Lilly. It is a triple hormone receptor agonist — targeting GIP, GLP-1, and glucagon receptors simultaneously — that has shown significant promise in clinical trials for the treatment of obesity. Early trial data suggested weight loss of up to 24% of body weight over 48 weeks, figures that attracted enormous attention in both the medical community and the general public.
However, retatrutide has not received regulatory approval for human use in any country. It remains in clinical trials, and the pharmaceutical-grade product is available only to trial participants under strict medical supervision. The drug that is circulating on the black market in Belfast and elsewhere is not pharmaceutical-grade retatrutide — it is an unregulated, non-pharmaceutical product sourced from overseas suppliers whose manufacturing standards are entirely unknown.
The emergence of a black market for weight-loss drugs in Northern Ireland is not a new phenomenon. The success of semaglutide (Wegovy) and tirzepatide (Mounjaro) — both of which are approved and available through legitimate medical channels — created a template for the illegal trade in similar compounds. When retatrutide's trial results became public, it was only a matter of time before unregulated versions began appearing on social media platforms.
Key Developments
Reports from the Irish News this week revealed the scale of the illegal trade in Belfast, with sellers using Facebook and other platforms to advertise pre-filled research pens containing retatrutide at prices ranging from £140 to £250. Sellers typically use coded language or claim the products are for research purposes to avoid content moderation, directing buyers to websites — including one called Clova Health — that facilitate the transactions.
Professor Donal O'Shea, a leading endocrinologist, has reported cases of patients presenting at hospitals with serious adverse effects after using retatrutide obtained from non-medical sources. The side effects include severe vomiting, diarrhoea, constipation, and in more serious cases, kidney disease and liver damage. The unregulated nature of the product means that patients have no way of knowing the actual concentration of the drug they are injecting, the purity of the compound, or the sterility of the preparation.
The Medicine Regulatory Group in Northern Ireland has seen a dramatic increase in the seizure of unlicensed weight-loss medications, with more than 2,200 products confiscated in 2026 alone. Eli Lilly has confirmed that it is working with law enforcement and social media companies to remove illegal listings, but the scale of the trade means that enforcement action is struggling to keep pace with the market.
Why It Matters
The illegal trade in weight-loss drugs reflects a broader public health challenge that is not unique to Northern Ireland but is particularly acute in a region where obesity rates are among the highest in the United Kingdom. NHS Northern Ireland's obesity management services, which provide access to approved medications such as Wegovy and Mounjaro, are under significant pressure, with waiting times for specialist assessment running into months. The gap between demand and legitimate supply creates the conditions in which an illegal market can flourish.
The specific risks associated with retatrutide are compounded by the fact that the drug is genuinely novel — its long-term safety profile is not yet established even in the controlled conditions of clinical trials. Patients who obtain it from unregulated sources are, in effect, conducting an uncontrolled experiment on themselves with a compound whose risks are not fully understood. The kidney disease cases reported by Professor O'Shea are particularly concerning, given that renal complications are not among the primary adverse effects identified in the clinical trial data.
For the Belfast Health and Social Care Trust and the other four HSC Trusts in Northern Ireland, the emergence of this illegal market creates additional pressure on emergency departments and specialist services that are already operating under significant strain. Patients presenting with adverse effects from unregulated drugs require investigation and treatment that consumes resources that would otherwise be available for other patients.
Local Impact
In Belfast, the illegal trade in Reta appears to be concentrated in gym and fitness communities, where personal trainers have been identified as a key distribution channel. The Royal Victoria Hospital and the Belfast City Hospital have both seen patients presenting with adverse effects, and clinical staff have been briefed on the signs and symptoms associated with retatrutide toxicity. The Public Health Agency has issued guidance to GPs across Northern Ireland advising them to ask patients about the use of weight-loss drugs obtained outside the healthcare system.
Community pharmacists across Belfast and the wider Northern Ireland area have been asked to be alert to patients seeking advice about weight-loss injections and to signpost them to legitimate NHS services. The Pharmacy Medicines Helpline has seen an increase in calls from people seeking information about the safety of products they have obtained online.
What's Next
The PSNI has confirmed that it is working with the Medicine Regulatory Group and with Eli Lilly to investigate the supply chain for illegal retatrutide in Northern Ireland. Arrests are expected in the coming weeks as the investigation progresses. Health authorities are urging anyone who has purchased retatrutide or similar products from social media or unverified online sources to consult their GP immediately and to bring the product with them for assessment. The Department of Health in Northern Ireland is expected to issue a formal public health advisory in the coming days, and the issue is likely to be raised at Stormont when the Assembly returns from recess.
